Equities Analysts Set Expectations for Harrow Q4 Earnings

Harrow, Inc. (NASDAQ:HROW) – Stock analysts at HC Wainwright boosted their Q4 2024 earnings per share (EPS) estimates for Harrow in a research report issued to clients and investors on Tuesday, March 18th. HC Wainwright analyst Y. Chen now forecasts that the company will earn $0.16 per share for the quarter, up from their prior forecast of ($0.07). HC Wainwright currently has a “Buy” rating and a $57.00 price target on the stock. The consensus estimate for Harrow’s current full-year earnings is ($0.53) per share. HC Wainwright also issued estimates for Harrow’s Q1 2025 earnings at $0.04 EPS, Q2 2025 earnings at $0.09 EPS, Q3 2025 earnings at $0.02 EPS, Q4 2025 earnings at $0.07 EPS and FY2025 earnings at $0.21 EPS.

Separately, B. Riley decreased their target price on Harrow from $73.00 to $69.00 and set a “buy” rating for the company in a report on Wednesday, December 4th.

Harrow Price Performance

Shares of Harrow stock opened at $28.41 on Friday. The company has a quick ratio of 1.44, a current ratio of 1.55 and a debt-to-equity ratio of 3.23. The company has a market cap of $1.01 billion, a PE ratio of -30.22 and a beta of 0.69. The business has a 50 day moving average of $29.51 and a 200 day moving average of $38.40. Harrow has a 52 week low of $9.86 and a 52 week high of $59.23.

Hedge Funds Weigh In On Harrow

A number of institutional investors have recently added to or reduced their stakes in HROW. Braidwell LP raised its holdings in Harrow by 106.3% in the fourth quarter. Braidwell LP now owns 907,039 shares of the company’s stock worth $30,431,000 after purchasing an additional 467,401 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in Harrow by 443.1% in the third quarter. JPMorgan Chase & Co. now owns 238,367 shares of the company’s stock worth $10,717,000 after purchasing an additional 194,480 shares in the last quarter. Charles Schwab Investment Management Inc. grew its stake in shares of Harrow by 195.9% in the third quarter. Charles Schwab Investment Management Inc. now owns 251,629 shares of the company’s stock worth $11,313,000 after acquiring an additional 166,602 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in shares of Harrow in the third quarter worth $5,864,000. Finally, Two Sigma Investments LP grew its stake in shares of Harrow by 483.2% in the fourth quarter. Two Sigma Investments LP now owns 150,355 shares of the company’s stock worth $5,044,000 after acquiring an additional 124,574 shares during the last quarter. Institutional investors own 72.76% of the company’s stock.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.